# NIDA Clinical Trials Network: New York Node

> **NIH NIH UG1** · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · 2020 · $2,448,086

## Abstract

The New York Node (NYN) of the NIDA CTN, led by John Rotrosen and Edward Nunes, represents the 2010
merger of the New York and Long Island Nodes, which had been part of the CTN since 2000 and 2001,
respectively. This fourth competing renewal application builds on both a strong and successful infrastructure to
manage clinical trials, and a track record of innovation and successful implementation of trials in mainstream
healthcare settings where most SUD patients are seen. We contribute expertise in virtually all key CTN
priorities outlined in RFA-DA-20-024, including: integration of SUD treatment and prevention in mainstream
settings (primary care, emergency departments, criminal justice); leveraging the electronic health record to
support improved and expanded care; developing medications and behavioral therapies; co-occurring medical
and psychiatric disorders; women and minorities; digital and other technology-based interventions; data
science including novel data analytic approaches; and implementation science, health economics, advocacy,
and policy to sustain evidence-based interventions. In the new funding period, the NYN will lead or co-lead
seven ambitious projects, all scheduled to begin in 2019 or 2020: CTN-0079-A1 Ancillary Study of the Adoption
and Sustainability of ED-Initiated Buprenorphine; CTN-0082 Implementation Survey of PrEP and Opioid Use
Related Services in STI Clinics and Community Based Organizations; CTN-0094 Individual Level Predictive
Modeling of Opioid Use Disorder Treatment Outcome; CTN-0096 Culturally Centered MAT for OUD
Implementation Facilitation for Primary Care and Addiction Treatment Programs Serving American
Indian/Alaska Natives; CTN-0097 Surmounting Withdrawal to Initiate Fast Treatment with Naltrexone (SWIFT):
Improving the Real-World Effectiveness of Injection Naltrexone for Opioid Use Disorder; CTN-0100 Optimizing
Retention, Duration, and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy; and CTN-0101
Subthreshold Opioid Use Disorder Prevention (STOP) Trial. We will also continue to help develop new trials in
CTN, including in the area of stimulant dependence, and to supply sites for CTN trials.
To support this, we have built a network of collaborating researchers, providers, and policy makers from
academia, community-based addiction treatment programs, large multifaceted healthcare systems, and NY
City and State agencies, all in the nation’s largest and most diverse metropolitan area. We have established a
track record of substantial contributions to the CTN, building on our work through deliberate, rigorous, and
stepwise improvements. Our vision for the Network’s future includes work built around addressing gaps
highlighted by the opioid treatment cascade, interventions for stimulant dependence, effective use of the CTN
platform to enable a broad range of non-CTN studies, and a continued commitment to training a new
generation of addictions clinical researchers. Further, we partner with im...

## Key facts

- **NIH application ID:** 10164508
- **Project number:** 3UG1DA013035-19S1
- **Recipient organization:** NEW YORK UNIVERSITY SCHOOL OF MEDICINE
- **Principal Investigator:** Edward V. Nunes
- **Activity code:** UG1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $2,448,086
- **Award type:** 3
- **Project period:** 2001-01-10 → 2025-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10164508

## Citation

> US National Institutes of Health, RePORTER application 10164508, NIDA Clinical Trials Network: New York Node (3UG1DA013035-19S1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10164508. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*